A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers

被引：0
|
作者：
Donghoon Shin
Yoon Jung Lee
Jihye Choi
Dahyoung Lee
Minjeong Park
Magdalena Petkova
机构：
[1] Samsung Bioepis Co.,Medical Affairs
[2] Ltd,Clinical Development
[3] Samsung Bioepis Co.,Biometrics
[4] Ltd,Clinical Bioanalysis
[5] Samsung Bioepis Co.,Clinical Pharmacology Unit
[6] Ltd,undefined
[7] Samsung Bioepis Co.,undefined
[8] Ltd,undefined
[9] SGS LSS,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
SB8; Bevacizumab; Biosimilar; Pharmacokinetics; Immunogenicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：567 / 575
页数：8
相关论文
共 50 条
  • [31] A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects
    Hanes, Vladimir
    Chow, Vincent
    Zhang, Nan
    Markus, Richard
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (05) : 881 - 888
  • [32] A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects
    Vladimir Hanes
    Vincent Chow
    Nan Zhang
    Richard Markus
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 881 - 888
  • [33] A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects
    Zhou, Renpeng
    Yang, Jingjing
    Liu, Yueyue
    Zhang, Qian
    Lu, Chao
    Tang, Ke
    Li, Xiao
    Tang, Wei
    Gao, Emei
    Wu, Can
    Dou, Changlin
    Hu, Wei
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (02) : 263 - 269
  • [34] A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT-P41 and reference denosumab in healthy males
    Kim, Anhye
    Hong, Jang Hee
    Shin, Wonsuk
    Yoo, Hyounggyoon
    Jung, Jin-Gyu
    Reginster, Jean-Yves
    Kim, Sunghyun
    Bae, Yunju
    Suh, Jeehye
    Kim, Sera
    Lee, Eunkyung
    Silverman, Stuart
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (07) : 655 - 663
  • [35] A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers
    Zhou, Huan
    Cao, Shugang
    Zhu, Xingyu
    Xie, Jing
    Fan, Ling
    Ge, Qin
    Wang, Ying
    Zhu, Juan
    Liu, Yuanyuan
    Shao, ZhongHuan
    Shan, Rongfang
    Liu, Bingyan
    Wang, Hongju
    Ding, Li
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (10) : 997 - 1003
  • [36] Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers
    Chukwuani, CM
    Coker, HAB
    Oduola, AMJ
    Ifudu, ND
    Sowunmi, A
    CHEMOTHERAPY, 1998, 44 (06) : 369 - 376
  • [37] Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers
    Stifft, Frank
    Vanmolkot, Floris
    Scheffers, Ingrid
    van Bortel, Luc
    Neef, Cees
    Christiaans, Maarten
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (05) : 996 - 1004
  • [38] A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects
    Hettema, Willem
    Wynne, Christopher
    Lang, Benjamin
    Altendorfer, Mario
    Czeloth, Niklas
    Lohmann, Ragna
    Athalye, Sandeep
    Schliephake, Dorothee
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (08) : 889 - 896
  • [39] A Randomized, Double-Blind, Parallel Controlled, Single-Dose Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of the Infliximab Biosimilar CMAB008 and the Reference Product in Healthy Chinese Male Subjects
    Zhou, Ruirui
    Chen, Qian
    Hou, Sheng
    Guo, Huaizu
    Li, Jing
    Qian, Weizhu
    Wang, Hao
    Ou, Lun
    Chen, XiaoFei
    Jiang, Fan
    Jia, Jingying
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (09): : 1028 - 1035
  • [40] Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study
    Yu, Kyung-Sang
    Kim, Byungwook
    Shin, Dongseong
    Park, Min Kyu
    Hwang, Jun Gi
    Kim, Min-Gul
    Chung, Hyewon
    Ghim, JongLyul
    Chung, Jae-Yong
    Smolen, Josef S.
    Burmester, Gerd R.
    Kim, SungHyun
    Bae, YunJu
    Jeon, DaBee
    Yoo, JaeKyoung
    Yang, GoEun
    Bae, JiHun
    Keystone, Edward
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, 32 (05) : 429 - 439
12345